BRIEF-Orchard Therapeutics Says $150 Mln Strategic Financing Supports Execution Into First Half Of 2023
BRIEF-Orchard Therapeutics Says $150 Mln Strategic Financing Supports Execution Into First Half Of 2023
* ORCHARD THERAPEUTICS REPORTS 2020 FINANCIAL RESULTS AND REVIEWS RECENT ACCOMPLISHMENTS
* ORCHARD THERAPEUTICS PLC - $150 MILLION STRATEGIC FINANCING SUPPORTS EXECUTION INTO FIRST HALF OF 2023
* ORCHARD THERAPEUTICS PLC - OTL-200 U.S. FILING STRATEGY FOR METACHROMATIC LEUKODYSTROPHY (MLD) EXPECTED BY MID-2021
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 2 (Reuters) - Orchard Therapeutics PLC :
* ORCHARD THERAPEUTICS REPORTS 2020 FINANCIAL RESULTS AND REVIEWS RECENT ACCOMPLISHMENTS
* ORCHARD THERAPEUTICS PLC - $150 MILLION STRATEGIC FINANCING SUPPORTS EXECUTION INTO FIRST HALF OF 2023
* ORCHARD THERAPEUTICS PLC - OTL-200 U.S. FILING STRATEGY FOR METACHROMATIC LEUKODYSTROPHY (MLD) EXPECTED BY MID-2021
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月2日電-Orchard Treeutics PLC：*Orchard Treeutics報告2020年財務業績並回顧近期成就*Orchard Treeutics PLC-1.5億美元戰略融資支持執行至2023年上半年*Orchard Treeutics PLC-OTL-200美國異色性腦白質營養不良(MLD)申請戰略預計將於2021年年中完成Eikon的源文本：進一步的公司報道：(Reurs.Briefs@thomsonreurs.com；)
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧